01—Abstract
Summary
Summary of the 8-K filed January 13, 2025. Cited figures are marked; the original filing is the authoritative source.
United Therapeutics Corporation furnished an investor presentation under Item 7.01 (Regulation FD) for its appearance at the 43rd annual J.P.
Morgan Healthcare Conference on January 13, 2025, from 2:15 p.m. to 2:55 p.m. Pacific Standard Time. The session was available by live webcast on the company's website, with an archived recording available about 24 hours after the session ends for 30 days.
The information is furnished, not filed, under Section 18 of the Exchange Act. The filing's Exhibit 99.1 is the investor presentation dated January 13, 2025. The presentation frames the company's growth in three waves: a foundation of a cash-generating commercial rare disease business, an innovation phase with a cascade of clinical and regulatory events over the next three years, and a longer revolution aimed at addressing the shortage of organs for transplant.
It cites nine consecutive quarters of double-digit year-over-year quarterly revenue growth, three years of double-digit annual revenue growth, a 23% revenue compound annual growth rate since Remodulin approval in 2002, and more than $1 billiona in annual operating cash flow for the trailing twelve months ending September 30, 2024. The company states it returned $1 billion to shareholders in 2024.
The presentation lists expected 2025 events including UKidney IND clearance, TETON 2 data in idiopathic pulmonary fibrosis (IPF), and the ADVANCE OUTCOMES study close in pulmonary arterial hypertension (PAH). It also cites a UKidney transplant completed at NYU on November 25, 2024, and notes all timing reflects current expectations that are subject to change.
02—Key points
Key Highlights
- Regulation FD disclosure: Investor presentation (Exhibit 99.1) for the J.P. Morgan Healthcare Conference on January 13, 2025, furnished rather than filed under the Exchange Act.
- Financial foundation: Nine consecutive quarters of double-digit year-over-year quarterly revenue growth and three years of double-digit annual revenue growth, with a 23% revenue CAGR since Remodulin approval in 2002.
- Cash generation: More than $1 billion in annual operating cash flow for the trailing twelve months ending September 30, 2024, and $1 billion returned to shareholders in 2024.
- Commercial position: Described as the most prescribed prostacyclin in the U.S., with 11 sequential quarters of year-over-year quarterly revenue growth.
- Pipeline catalysts: TETON 2 data in IPF expected in 2025, ralinepag NDA for PAH expected in 2026 with data from the ADVANCE OUTCOMES study, and a TETON 1 data readout in 2026.
- Xenotransplantation: UKidney IND submitted and awaiting clearance; a UKidney transplant was completed at NYU on November 25, 2024, with initial discharge on December 6, 2024.
- Long-term outlook: Management presents a three-wave growth framework and a 36-month cascade of potential clinical and regulatory catalysts starting in 2025, with timing subject to change.
03—Questions
Frequently Asked Questions
What is the purpose of this 8-K filing?
The company is furnishing an investor presentation for its appearance at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025. The information is furnished under Item 7.01 and is not deemed filed for Exchange Act Section 18 purposes.
How strong is the company's revenue and cash flow profile according to the presentation?
The presentation cites nine consecutive quarters of double-digit year-over-year quarterly revenue growth, three years of double-digit annual revenue growth, and a 23% revenue CAGR since Remodulin approval in 2002. It also reports more than $1 billion in annual operating cash flow for the trailing twelve months ending September 30, 2024.
What clinical and regulatory events does the company expect in the near term?
The presentation lists 2025 events including UKidney IND clearance, TETON 2 data in IPF, and the ADVANCE OUTCOMES study close in PAH. For 2026 it lists TETON 1 data in IPF, a nebulized Tyvaso sNDA for IPF, ADVANCE OUTCOMES data in PAH, and a ralinepag NDA for PAH. It notes these timings are current expectations and subject to change.
What is the status of the company's xenotransplantation program?
The presentation states the UKidney IND has been submitted and is awaiting clearance. It reports a UKidney transplant completed at NYU on November 25, 2024, with initial discharge on December 6, 2024, and the recipient doing well.
How does the company describe its capital returns?
The presentation states the company returned $1 billion to shareholders in 2024 and describes a rigid budget algorithm under which no more than 50% of prior year revenue is spent on cash operating expenses.
04—Continue